Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Enveric Biosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 147.6K | 173.3K | +25.7K (+17.4%) |
| Value | $623.0K | $356.8K | −$266.2K (−42.7%) |
New holders (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Credit Suisse AG | 1 | $2 | 0.00% |
| Advisor Group Holdings, Inc. | 150 | $0 | 0.00% |
Sold out (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Hudson Bay Capital Management LP | 10,906 | $46.0K |
| FMR LLC | 1 | $0 |